← Research library

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration

Comparison in people · 2021

What was studied
38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Main finding
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Visual acuity · Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.

Reported findings and study design

Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.

Population or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.

Results · Original publisher PDF, methods and Tables 1–2
MeasureResultComparison, timing and statistics
Visual acuityRetinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.
Electroretinogram a-wave amplitudeRetinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV.
Electroretinogram b-wave amplitudeRetinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV.

The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated.
  • The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified.
  • The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.

Source details

Original journal report

Original Russian article, treatment methods and Tables 1 and 2.

Sources checked

Citation

Human comparative studyFull text available

A. V. Derkach, S. V. Trofimova. Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration Vrach. 2021;32(5):85–87.

Study source ↗ · DOI 10.29296/25877305-2021-05-16 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards